Rapid Haemodynamic Improvement Following Saruplase in Recent Massive Pulmonary Embolism

Summary

In a single centre pilot study, saruplase (20 mg bolus plus 60 mg infusion over 1 h) was administered to twenty patients with an angio-graphically documented recent massive pulmonary embolism: Miller index of at least 20 and mean pulmonary artery pressure of at least 20 mmHg. The lytic ability of saruplase to cause normalization of haemodynamic parameters over the first 12 h and reperfusion of pulmonary arteries at 24 h was assessed. A decrease of 25 ± 10% in total pul monary resistance was evident at 30 min. Haemodynamic parameters continued to improve with total pulmonary resistance decreasing by 29 ± 8% and 40 ± 11% at 1 and 12 h respectively. Relative improve ment in Miller index 24 ± 6 h after saruplase treatment was 38 ± 9%. Two patients suffered recurrent pulmonary embolism, two severe bleeding events were observed. One patient died following a haemorrhagic stroke.

• References

• 1 Meyer G, Charbonnier B, Stern M, Brochier ML, Sors H. Thrombolysis in acute pulmonary embolism. In: Thrombolysis in Cardiovascular Disease. Julian D, Kübler W, Norris RM, Swan HJC, Collen D, Verstraete M. eds. Basel, New York: Marcel Dekker Company; 1989: 337-60.
• 2 Petitpretz P, Simonneau G, Cerrina J, Musset D, Dreyfus M, Vandenbroek MD, Duroux P. Effects of a single bolus of Urokinase in patients with life-threatening pulmonary emboli: a descriptive trial. Circulation 1984; 70: 861-6.
• 3 Meyer G, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, Lesaffre E, Vanhove P, Verstraete M. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicentre double-blind trial. J Am Coll Cardiol 1992; 19: 239-45.
• 4 Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simonneau G. Hemodynamic effects of bolus versus 2 h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest 1994; 106: 712-7.
• 5 PRIMI Trial Study Group.. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989; 1: 863-8.
• 6 Meneveau N, Bassand JP, Schiele F, Boura Y, Anguenot T, Bernrd Y, Schultz R. Safety of thrombolytic therapy in elderly patients with massive pulmonary embolism: a comparison with non elderly patients. J Am Coll Cardiol 1993; 2: 1075-9.
• 7 Flohé L. Recombinant human pro-urokinase (non-glycosylated). Drugs Future 1986; 11: 851-2.
• 8 Miller GAH, Sutton GS, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and heparin in treatment of isolated massive pulmonary embolism. Br Med J 1971; 2: 681-4.
• 9 Brochier M, Raynaud P, Fauchier JP, Charbonnier B, Latour F, Alison A, Pellois A, Planiol T. Comparison between lung scans and pulmonary angio-grams in the evaluation of the perfusion defect in massive and submassive pulmonary embolism. Prog Resp Res (Karger, Basel) 1980; 13: 120-6.
• 10 Vermeer F, Bär FW, Windeler J, Schenkel W. Saruplase: a new fibrin spe cific thrombolytic agent. Final results of the PASS study (1698 patients). Circulation 1993; 88: I.292.
• 11 Diehl JL, Meyer G, Igual J, Collignon AMA, Giselbrecht M, Even P, Sors H. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism. Am J Cardiol 1992; 70: 1477-80.
• 12 Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, Gent M. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98: 1473-9.